Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Instil Bio, Inc.NASDAQ: TIL
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $17K, compared with -$376K a year earlier. Trailing-twelve-month accounts payables was $509K.
Context
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $17K or moves back toward the trailing-twelve-month quarterly average of $127.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 116K USD
- Year-over-year change
- +120.9%
- 4-year CAGR
- -58.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116K | +120.9% |
| FY2024 | 2024-12-31 | (556K) | +50.8% |
| FY2023 | 2023-12-31 | (1.13M) | +37.5% |
| FY2022 | 2022-12-31 | (1.81M) | -146.8% |
| FY2021 | 2021-12-31 | 3.86M | — |
Accounts Payables vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +153.5% is the 3rd highest of 6, against a peer median of +89.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.77M USD | +201.6% | — | — | |
| LTM Mar 2026 | €6.32M EUR | — | +17.8% | 21552.6% | |
| LTM Mar 2026 | $5.26M USD | +350.7% | +59.5% | — | |
| LTM Mar 2026 | $2.31M USD | -48.2% | -70.5% | 1.5% | |
| LTM Mar 2026 | CA$1.13M CAD | — | — | — | |
| LTM Mar 2026 | $509K USD | +153.5% | — | — | |
| LTM Mar 2026 | $343K USD | -64.3% | -51.8% | 34.3% | |
| LTM Mar 2026 | $307K USD | +89.5% | — | 4.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding TIL) | — | +89.5% | -17.0% | 4.1% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| Deferred Income Tax | 710K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M |
| Change in Working Capital | 4.36M | (9.57M) | (9.02M) | (12.61M) | (560K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (3.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (1.81M) | (1.13M) | (556K) | 116K |
| Other Working Capital | 499K | (7.76M) | (7.89M) | (12.05M) | 2.72M |
| Other Non-Cash Items | 636K | 16.15M | 60.15M | 10.18M | 26.09M |
| Operating Cash Flow | (122.14M) | (180.16M) | (82.03M) | (55.7M) | (36.62M) |
| Capital Expenditures | (57.83M) | (84.59M) | (20.66M) | (10M) | 0 |
| Acquisitions (Net) | 0 | 1.17M | 0 | 0 | 432K |
| Purchases of Investments | (1.11B) | (666.22M) | (301.47M) | (135.6M) | (100.86M) |
| Sales of Investments | 691M | 865.35M | 361.7M | 198.71M | 135.9M |
| Other Investing Activities | 0 | (1.17M) | 1.56M | 866K | 0 |
| Investing Cash Flow | (474.4M) | 114.54M | 41.13M | 53.97M | 25.48M |
| Debt Repayment | 0 | 70.34M | 8.08M | 2.76M | 6.61M |
| Common Stock Issued | 339.02M | 1.55M | 0 | 0 | 853K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.69M | 0 | 0 | (1.01M) | (172K) |
| Financing Cash Flow | 393.16M | 71.89M | 8.08M | 1.76M | 7.29M |
| Effect of Forex Changes | (304K) | (637K) | (201K) | (94K) | 20K |
| Net Change in Cash | (203.67M) | 5.63M | (33.02M) | (61K) | (3.83M) |
| Free Cash Flow | (179.97M) | (264.75M) | (102.69M) | (65.7M) | (36.62M) |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.